描述
Powered by Eupheria Biotech
產品線
MISSION®
形狀
lyophilized powder
esiRNA cDNA 標靶序列
GGAGTGGTTCCAAGTTTCCAGTATTCAATATGTCATACAATCCAGCAGAAAATGCAGTCCTGCTTTGTACAAGAGCTAGCAATCTAGAGAATAGTACCTATGACCTGTACACCATCCCTAAAGATGCTGACTCCCAGAATCCTGATGCGCCTGAAGGGAAACGATCCTCAGGCCTGACAGCCGTTTGGGTCGCTCGAAATCGGTTTGCTGTCCTAGATCGGATGCATTCGCTTCTGATCAAGAATCTGAAGAATGAGATCACCAAAAAGGTACAGGTGCCCAACTGTGATGAGATCTTCTATGCTGGCACAGGCAATCTCCTGCTTCGAGATGCGGACTCTATCACACTCTTTGACGTACAGCAGAAGCGGACTCTGGCATCTGTGAAGATTTCTAAAGTGAAATACGTTATCTGGTCAGCAGACATGTCACATGTAGCACTACTAGCCAAACACGCCATTGTGATCTGTAACCGCAAACTGGATGCT
Ensembl | 人類登錄號
NCBI登錄號
運輸包裝
ambient
儲存溫度
−20°C
基因資訊
human ... COPA(1314) , COPA(1314)
相关类别
一般說明
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
法律資訊
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
10 - Combustible liquids
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Cancer cell, 33(5), 817-828 (2018-05-01)
Adenosine (A) to inosine (I) RNA editing introduces many nucleotide changes in cancer transcriptomes. However, due to the complexity of post-transcriptional regulation, the contribution of RNA editing to proteomic diversity in human cancers remains unclear. Here, we performed an integrated
The Journal of experimental medicine, 217(11) (2020-07-30)
Heterozygous missense mutations in coatomer protein subunit α, COPA, cause a syndrome overlapping clinically with type I IFN-mediated disease due to gain-of-function in STING, a key adaptor of IFN signaling. Recently, increased levels of IFN-stimulated genes (ISGs) were described in
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门